NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
22 août 2024 07h00 HE
|
Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
American Institutes for Research To Help Implement Federal Program Aimed at Increasing Access to Transformative Cell and Gene Therapy Treatments
21 août 2024 12h00 HE
|
American Institutes for Research
Arlington, Va., Aug. 21, 2024 (GLOBE NEWSWIRE) -- The American Institutes for Research (AIR) has been awarded a federal contract to help implement and monitor a new program that seeks to make...
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
15 août 2024 07h00 HE
|
Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h05 HE
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14 août 2024 16h01 HE
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13 août 2024 16h05 HE
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Immatics Announces Second Quarter 2024 Financial Results and Business Update
13 août 2024 07h00 HE
|
https://immatics.com/
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of...
Cell Therapy Biomanufacturing Market Report 2024: Market Revenue Data from 2022, Estimates for 2023, Forecasts for 2024 and Projected CAGRs through 2029
09 août 2024 05h41 HE
|
Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing Market 2024-2029" report has been added to ResearchAndMarkets.com's offering. The cell therapy biomanufacturing global...
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
05 août 2024 16h05 HE
|
Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.